Literature DB >> 22891268

Response to crizotinib in ROS1-rearranged non-small-cell lung cancer.

Takefumi Komiya, Anish Thomas, Sean Khozin, Arun Rajan, Yisong Wang, Giuseppe Giaccone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22891268     DOI： 10.1200/JCO.2012.42.4556

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

Review 1.  Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.

Authors:  Takashi Kohno; Takashi Nakaoku; Koji Tsuta; Katsuya Tsuchihara; Shingo Matsumoto; Kiyotaka Yoh; Koichi Goto
Journal:  Transl Lung Cancer Res       Date:  2015-04

Review 2.  Molecular testing in lung cancer in the era of precision medicine.

Authors:  Helmut H Popper; Ales Ryska; József Tímár; Wlodzimierz Olszewski
Journal:  Transl Lung Cancer Res       Date:  2014-10

3.  ROS1 mutation and treatment with crizotinib in a 30-year old Caucasian woman with stage IV non-small cell lung cancer/adenocarcinoma and complete remission.

Authors:  Markus Blaukovitsch; Johann Hofer; Georg Hutarew; Leonhard Müllauer; Simonitsch-Klupp Ingrid; Michael Studnicka
Journal:  Thorac Cancer       Date:  2014-08-25       Impact factor: 3.500

4.  Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.

Authors:  Bo Mi Ku; Yeon Hee Bae; Kyoung Young Lee; Jong-Mu Sun; Se-Hoon Lee; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn
Journal:  Invest New Drugs       Date:  2019-05-24       Impact factor: 3.850

5.  The ortholog of the human proto-oncogene ROS1 is required for epithelial development in C. elegans.

Authors:  Martin R Jones; Ann M Rose; David L Baillie
Journal:  Genesis       Date:  2013-06-27       Impact factor: 2.487
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.